KeyLynk-009
NCT04191135
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Status:
Recruiting
II, III
Phase
1st
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
TNBC
Investigational
Product
Treatment Arms
o pembrolizumab + carboplatin and gemcitabine
o pembrolizumab + olaparib